Cargando…

Therapeutic target-site variability in α(1)-antitrypsin characterized at high resolution

The intrinsic propensity of α(1)-antitrypsin to undergo conformational transitions from its metastable native state to hyperstable forms provides a motive force for its antiprotease function. However, aberrant conformational change can also occur via an intermolecular linkage that results in polymer...

Descripción completa

Detalles Bibliográficos
Autores principales: Patschull, Anathe O. M., Segu, Lakshmi, Nyon, Mun Peak, Lomas, David A., Nobeli, Irene, Barrett, Tracey E., Gooptu, Bibek
Formato: Online Artículo Texto
Lenguaje:English
Publicado: International Union of Crystallography 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3232123/
https://www.ncbi.nlm.nih.gov/pubmed/22139150
http://dx.doi.org/10.1107/S1744309111040267
_version_ 1782218327502880768
author Patschull, Anathe O. M.
Segu, Lakshmi
Nyon, Mun Peak
Lomas, David A.
Nobeli, Irene
Barrett, Tracey E.
Gooptu, Bibek
author_facet Patschull, Anathe O. M.
Segu, Lakshmi
Nyon, Mun Peak
Lomas, David A.
Nobeli, Irene
Barrett, Tracey E.
Gooptu, Bibek
author_sort Patschull, Anathe O. M.
collection PubMed
description The intrinsic propensity of α(1)-antitrypsin to undergo conformational transitions from its metastable native state to hyperstable forms provides a motive force for its antiprotease function. However, aberrant conformational change can also occur via an intermolecular linkage that results in polymerization. This has both loss-of-function and gain-of-function effects that lead to deficiency of the protein in human circulation, emphysema and hepatic cirrhosis. One of the most promising therapeutic strategies being developed to treat this disease targets small molecules to an allosteric site in the α(1)-antitrypsin molecule. Partial filling of this site impedes polymerization without abolishing function. Drug development can be improved by optimizing data on the structure and dynamics of this site. A new 1.8 Å resolution structure of α(1)-antitrypsin demonstrates structural variability within this site, with associated fluctuations in its upper and lower entrance grooves and ligand-binding characteristics around the innermost stable enclosed hydrophobic recess. These data will allow a broader selection of chemotypes and derivatives to be tested in silico and in vitro when screening and developing compounds to modulate conformational change to block the pathological mechanism while preserving function.
format Online
Article
Text
id pubmed-3232123
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher International Union of Crystallography
record_format MEDLINE/PubMed
spelling pubmed-32321232011-12-12 Therapeutic target-site variability in α(1)-antitrypsin characterized at high resolution Patschull, Anathe O. M. Segu, Lakshmi Nyon, Mun Peak Lomas, David A. Nobeli, Irene Barrett, Tracey E. Gooptu, Bibek Acta Crystallogr Sect F Struct Biol Cryst Commun Structural Communications The intrinsic propensity of α(1)-antitrypsin to undergo conformational transitions from its metastable native state to hyperstable forms provides a motive force for its antiprotease function. However, aberrant conformational change can also occur via an intermolecular linkage that results in polymerization. This has both loss-of-function and gain-of-function effects that lead to deficiency of the protein in human circulation, emphysema and hepatic cirrhosis. One of the most promising therapeutic strategies being developed to treat this disease targets small molecules to an allosteric site in the α(1)-antitrypsin molecule. Partial filling of this site impedes polymerization without abolishing function. Drug development can be improved by optimizing data on the structure and dynamics of this site. A new 1.8 Å resolution structure of α(1)-antitrypsin demonstrates structural variability within this site, with associated fluctuations in its upper and lower entrance grooves and ligand-binding characteristics around the innermost stable enclosed hydrophobic recess. These data will allow a broader selection of chemotypes and derivatives to be tested in silico and in vitro when screening and developing compounds to modulate conformational change to block the pathological mechanism while preserving function. International Union of Crystallography 2011-11-25 /pmc/articles/PMC3232123/ /pubmed/22139150 http://dx.doi.org/10.1107/S1744309111040267 Text en © Patschull et al. 2011 http://creativecommons.org/licenses/by/2.0/uk/ This is an open-access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original authors and source are cited.
spellingShingle Structural Communications
Patschull, Anathe O. M.
Segu, Lakshmi
Nyon, Mun Peak
Lomas, David A.
Nobeli, Irene
Barrett, Tracey E.
Gooptu, Bibek
Therapeutic target-site variability in α(1)-antitrypsin characterized at high resolution
title Therapeutic target-site variability in α(1)-antitrypsin characterized at high resolution
title_full Therapeutic target-site variability in α(1)-antitrypsin characterized at high resolution
title_fullStr Therapeutic target-site variability in α(1)-antitrypsin characterized at high resolution
title_full_unstemmed Therapeutic target-site variability in α(1)-antitrypsin characterized at high resolution
title_short Therapeutic target-site variability in α(1)-antitrypsin characterized at high resolution
title_sort therapeutic target-site variability in α(1)-antitrypsin characterized at high resolution
topic Structural Communications
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3232123/
https://www.ncbi.nlm.nih.gov/pubmed/22139150
http://dx.doi.org/10.1107/S1744309111040267
work_keys_str_mv AT patschullanatheom therapeutictargetsitevariabilityina1antitrypsincharacterizedathighresolution
AT segulakshmi therapeutictargetsitevariabilityina1antitrypsincharacterizedathighresolution
AT nyonmunpeak therapeutictargetsitevariabilityina1antitrypsincharacterizedathighresolution
AT lomasdavida therapeutictargetsitevariabilityina1antitrypsincharacterizedathighresolution
AT nobeliirene therapeutictargetsitevariabilityina1antitrypsincharacterizedathighresolution
AT barretttraceye therapeutictargetsitevariabilityina1antitrypsincharacterizedathighresolution
AT gooptubibek therapeutictargetsitevariabilityina1antitrypsincharacterizedathighresolution